Emak SpA
MIL:EM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Emak SpA
Emak SpA
Capital Expenditures
Emak SpA
Capital Expenditures Peer Comparison
DLG
INDB
ELC
SAB
ARIS
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Emak SpA
MIL:EM
|
Capital Expenditures
-€22.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
|
De' Longhi SpA
MIL:DLG
|
Capital Expenditures
-€95.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Indel B SpA
MIL:INDB
|
Capital Expenditures
-€8.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Elica SpA
MIL:ELC
|
Capital Expenditures
-€16.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Sabaf SpA
MIL:SAB
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ariston Holding NV
MIL:ARIS
|
Capital Expenditures
-€158.6m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is Emak SpA's Capital Expenditures?
Capital Expenditures
-22.1m
EUR
Based on the financial report for Mar 31, 2024, Emak SpA's Capital Expenditures amounts to -22.1m EUR.
What is Emak SpA's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-10%
Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for Emak SpA have been -14% over the past three years , 1% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
